Table 1 Patients’ characteristics and factors affecting CR in 102 evaluable treated AML patients
Factors | Number of patients | Complete remission N (%) | p |
|---|---|---|---|
Age (years) | |||
 < 60 | 79 | 61 (77) | 0.019 |
 ≥ 60 | 23 | 12 (52) | |
White blood cell count | |||
 < 100,000/μL | 20 | 14 (70) | 0.862 |
 > 100,000/μL | 82 | 59 (72) | |
Cytogenetic risk | |||
 Favorable | 7 | 6 (86) | 0.051 |
 Intermediate | 71 | 54 (76) | |
 Adverse | 24 | 13 (54) | |
Gene mutation | |||
 FLT3-ITD | 8 | 5 (63) | 0.453 |
 NPM1 | 13 | 11 (85) | |
 FLT3-ITD and NPM1 | 6 | 5 (83) | |
 CEBPA | 10 | 7 (70) | |
 No mutation | 64 | 46 (72) | |
 Co-existence of mutant CEBPA with other gene mutation | 1 | 1 (100) | |
Single FLT3-ITD mutation | |||
 Yes | 8 | 5 (63) | 0.554 |
 No | 94 | 68 (72) | |
Single NPM1 mutation | |||
 Yes | 13 | 11 (85) | 0.100 |
 No | 89 | 62 (70) | |
Single CEBPA mutation | |||
 Yes | 10 | 7 (70) | 0.198 |
 No | 92 | 65 (71) | |
Induction chemotherapy | |||
 7 + 3 | 80 | 61 (76) | 0.000 |
 5 + 2 | 16 | 12 (75) | |
 Azacitidine | 6 | 0 | |